DSM to Highlight Vitamin and Lipid Portfolio at CPhI Worldwide 2018
The company will showcase the evolving role of vitamins and lipid APIs in pharmaceutical applications at CPhI Worldwide 2018.
DSM, a supplier of vitamins, carotenoids, and lipid APIs, will exhibit its portfolio of vitamins and lipid APIs at CPhI Worldwide, taking place in Madrid, Spain on Oct. 9–11, 2018.
The company’s pipeline is focused on addressing the latest research on the therapeutic effects of vitamins, as well as the development of vitamin combinations with established APIs. While combinations such as nonsteroidal anti-inflammatory drugs with B vitamins and contraceptives with folate are commercially available in several countries, DSM brings vitamin combinations to market for indications such as chronic low back pain, osteoarthritis, hypertension, type 2 diabetes, inflammatory bowel disease, and ulcer treatment.
DSM can provide access to both United States drug master files and certificates of suitability for all 13 of its vitamins, providing its pharmaceutical partners an advantage by accelerating the registration and market entry process, which enables timelier patient access, the company reports.
The company’s expertise in chemical synthesis and biotechnology helps to ensure products meet sustainability standards. Learn more at Stand 7B10 at 4pm–6pm on Oct. 9 and 10 at CPhI Worldwide 2018.
Source: DSM
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
